Correction: Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach.

Correction: Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach.

[This corrects the article DOI: 10.1371/journal.pone.0233335.].

Bibliographic Details
Main Authors:	Islam M Ghazi, Wasim S El Nekidy, Regan Asay, Paul Fimognari, Anthony Knarr, Mina Awad
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2020-01-01
Series:	PLoS ONE
Online Access:	https://doi.org/10.1371/journal.pone.0235405

Similar Items

Simultaneous administration of imipenem/cilastatin/relebactam with selected intravenous antimicrobials, a stewardship approach.
by: Islam M Ghazi, et al.
Published: (2020-01-01)

The Pattern of Imipenem/Cilastatin Administration in Imam Khomeini Hospital (Ardabil) in 2018
by: Moien Zakavati, et al.
Published: (2019-04-01)

A Clinical Review and Critical Evaluation of Imipenem-Relebactam: Evidence to Date
by: Campanella TA, et al.
Published: (2020-11-01)

Nontherapeutic equivalence of a generic product of imipenem-cilastatin is caused more by chemical instability of the active pharmaceutical ingredient (imipenem) than by its substandard amount of cilastatin.
by: Maria Agudelo, et al.
Published: (2019-01-01)

Population Pharmacokinetic Analysis for Imipenem–Relebactam in Healthy Volunteers and Patients With Bacterial Infections
by: Pratik Bhagunde, et al.
Published: (2019-10-01)

In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa
by: Katherine Young, et al.
Published: (2019-07-01)

A translational pharmacokinetic/pharmacodynamic model to characterize bacterial kill in the presence of imipenem-relebactam
by: Pratik Bhagunde, et al.
Published: (2019-12-01)

Evaluation of the appropriateness of imipenem/cilastatin prescription and dosing in a tertiary care hospital
by: Kabbara WK, et al.
Published: (2015-03-01)

Imipenem/cilastatin encapsulated polymeric nanoparticles for destroying carbapenem-resistant bacterial isolates
by: Mona I. Shaaban, et al.
Published: (2017-04-01)

Organic anion transporters also mediate the drug–drug interaction between imipenem and cilastatin
by: Yanna Zhu, et al.
Published: (2020-03-01)

Randomized Comparison of Piperacillin/Tazobactam Versus Imipenem/Cilastatin in the Treatment of Patients with Intra-abdominal Infection
by: Alex A. Erasmo
Published: (2004-07-01)

Activity of Ceftolozane/tazobactam and Imipenem/relebactam against Clinical Enterobacteriaceae Isolates Collected in the Middle East – SMART 2016-2018
by: I Alekseeva, et al.
Published: (2020-02-01)

Cilastatin protects against imipenem-induced nephrotoxicity via inhibition of renal organic anion transporters (OATs)
by: Xiaokui Huo, et al.
Published: (2019-09-01)

Treatment of Ventilator-Associated Gram-Negative Pneumonia with Imipenem-Cilastatin/Amikacin Versus Ticarcillin-Clavulanate/Amikacin
by: Ahmet ELALDI, et al.
Published: (2006-06-01)

Bacteremia caused by Elizabethkingia meningoseptica in a mechanically ventilated patient successfully treated with imipenem-cilastatin and ciprofloxacin
by: Chang-Hua Chen, et al.

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical P. aeruginosa isolates collected in the Middle East – SMART 2016-2018
by: I Alekseeva, et al.
Published: (2020-02-01)

Imipenem/Cilastatin versus Cefepime as Empiric Monotherapy for Fever in Neutropenic Patients after ematopoietic Stem Cell Transplantation
by: C Kani, et al.
Published: (2005-06-01)

A Prospective Randomized Trial of Imipenem-Cilastatin Versus Clindamycin/Tobramycin in the Treatmentof Intra-Abdominal and Pelvic Infections
by: Lionel A Mandell, et al.
Published: (1993-01-01)

Rapid Detection of KPC-Producing Enterobacterales Susceptible to Imipenem/Relebactam by Using the MALDI-TOF MS MBT STAR-Carba IVD Assay
by: Marina Oviaño, et al.
Published: (2020-02-01)

Imipenem/Cilastatin versus Cefepime as Empiric Monotherapy for Fever in Neutropenic Patients after ematopoietic Stem Cell Transplan¬tation
by: Kani C., et al.
Published: (2005-07-01)

Validated Reverse Phase HPLC Method for the Determination of DEHP Content in Reconstituting Diluents and in Reconstituted Solutions of Imipenem and Cilastatin for Injection
by: A. K. Chaudhary, et al.
Published: (2010-01-01)

Retrospective evaluation of piperacillin–tazobactam, imipenem–cilastatin and meropenem used on surgical floors at a tertiary care hospital in Saudi Arabia
by: Eman Youssif, et al.
Published: (2018-07-01)

Susceptibility to Imipenem/Relebactam of Pseudomonas aeruginosa and Acinetobacter baumannii Isolates from Chinese Intra-Abdominal, Respiratory and Urinary Tract Infections: SMART 2015 to 2018
by: Zhang H, et al.
Published: (2021-08-01)

Efficacy and safety of tigecycline monotherapy vs. imipenem/cilastatin in Chinese patients with complicated intra-abdominal infections: a randomized controlled trial
by: Chen Xiaoping, et al.
Published: (2010-07-01)

A novel analytical method to assess the effect of imipenem/cilastatin on liver function laboratory indexes in Chinese underage inpatients: Probability distribution curve.
by: Le Zou, et al.
Published: (2019-01-01)

In vitro activity of imipenem/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015–2017
by: James A. Karlowsky, et al.
Published: (2020-06-01)

A multicenter, double-blind, randomized, comparison study of the efficacy and safety of tigecycline to imipenem/cilastatin to treat complicated intra-abdominal infections in hospitalized subjects in China
by: Chen Y, et al.
Published: (2018-11-01)

Treatment of recurrent urinary tract infections in anuric hemodialysis patient, do we really need antimicrobial urinary concentration?
by: Wasim S. El Nekidy, et al.
Published: (2020-01-01)

Clostridium difficile infection risk of recurrence and candidates for preventive therapy, a stewardship approach
by: I. Ghazi, et al.
Published: (2020-12-01)

Protective Effects of Cilastatin against Vancomycin-Induced Nephrotoxicity
by: Blanca Humanes, et al.
Published: (2015-01-01)

Socratic antimicrobial stewardship
by: W. Elamin
Published: (2020-12-01)

The glocalization of antimicrobial stewardship
by: Olivier Rubin
Published: (2019-09-01)

Lipid imaging for visualizing cilastatin amelioration of cisplatin-induced nephrotoxicity
by: Estefanía Moreno-Gordaliza, et al.
Published: (2018-09-01)

ANTIMICROBIAL EVALUATION OF SESQUITERPENE α-CURCUMENE AND ITS SYNERGISM WITH IMIPENEM
by: Gloria Narjara Santos da Silva, et al.
Published: (2015-04-01)

Impact of printed antimicrobial stewardship recommendations on early intravenous to oral antibiotics switch practice in district hospitals
by: Sze WT, et al.
Published: (2018-06-01)

Antimicrobial Stewardship in the Neonatal Population
by: Duchon, Jennifer
Published: (2021)

Antimicrobial Stewardship: An Indian Perspective
by: Mani G, et al.
Published: (2014-08-01)

Antimicrobial Stewardship at The Toronto Hospital
by: Monique Pitre, et al.
Published: (1998-01-01)

Antimicrobial stewardship: Limits for implementation
by: B. Sinha
Published: (2014-04-01)

Antimicrobial stewardship - what is possible
by: Pauline Roberts
Published: (2021-02-01)